ELOVL5 Regulates Ferroptosis in Breast Cancer Cells

Area of Science:

• Oncology
• Molecular Biology
• Cell Death Research

Background:

• Breast cancer (BC) is a leading cause of cancer mortality globally.
• Ferroptosis, a distinct form of cell death, shows promise for treating BC resistant to conventional therapies.
• The ELOVL5 gene, crucial for fatty acid elongation, has been linked to BC progression.

Purpose of the Study:

• To investigate the impact of ELOVL5 gene knockdown on ferroptosis induction in MDA-MB-231 breast cancer cells.
• To analyze gene expression changes under the influence of docosahexaenoic acid (DHA) and erastin.
• To explore the role of ELOVL5 in regulating ferroptosis for potential targeted BC therapy.

Main Methods:

• Utilized ELOVL5 gene knockdown in MDA-MB-231 cells.
• Administered docosahexaenoic acid (DHA) and erastin to induce ferroptosis.
• Employed ferroptosis inhibitors (ferrostatin-1, deferoxamine) to validate pathway involvement.
• Conducted comparative gene expression analysis.

Main Results:

• Decreased ELOVL5 expression significantly increased MDA-MB-231 cell sensitivity to ferroptosis.
• Docosahexaenoic acid (DHA) induced earlier cell death compared to erastin.
• Ferroptosis inhibitors confirmed the pathway's role in the observed effects.
• Distinct gene expression patterns related to oxidative stress, inflammation, and proliferation were identified, suggesting varied ferroptosis mechanisms.

Conclusions:

• ELOVL5 gene expression critically influences breast cancer cell susceptibility to ferroptosis.
• Targeting ELOVL5 may enhance the efficacy of ferroptosis-inducing agents in breast cancer treatment.
• This research provides deeper insights into ELOVL5's regulatory role in ferroptosis, paving the way for novel therapeutic strategies.